Teva Pharmaceutical Industries Free Cash Flow 2006-2021 | TEVA

Teva Pharmaceutical Industries annual/quarterly free cash flow history and growth rate from 2006 to 2021. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
  • Teva Pharmaceutical Industries free cash flow for the quarter ending March 31, 2021 was -417.00, a year-over-year.
  • Teva Pharmaceutical Industries free cash flow for the twelve months ending March 31, 2021 was , a year-over-year.
  • Teva Pharmaceutical Industries annual free cash flow for 2020 was $0.705B, a 24.56% increase from 2019.
  • Teva Pharmaceutical Industries annual free cash flow for 2019 was $0.566B, a 78.92% decline from 2018.
  • Teva Pharmaceutical Industries annual free cash flow for 2018 was $2.685B, a 44.39% decline from 2017.
Teva Pharmaceutical Industries Annual Free Cash Flow
2020 705.00
2019 566.00
2018 2,685.00
2017 4,828.00
2016 6,326.00
2015 5,294.00
2014 4,394.00
2013 2,393.00
2012 3,732.00
2011 3,360.00
2010 4,126.00
2009 2,925.00
2008 2,550.00
2007 1,271.00
2006 1,668.00
2005 1,063.20
Teva Pharmaceutical Industries Quarterly Free Cash Flow
2021-03-31 -417.00
2020-12-31 705.00
2020-09-30 537.00
2020-06-30 364.00
2020-03-31 183.00
2019-12-31 566.00
2019-09-30 -29.00
2019-06-30 -218.00
2019-03-31 -2.00
2018-12-31 2,685.00
2018-09-30 1,641.00
2018-06-30 2,200.00
2018-03-31 2,157.00
2017-12-31 4,828.00
2017-09-30 2,366.00
2017-06-30 1,661.00
2017-03-31 1,346.00
2016-12-31 6,326.00
2016-09-30 5,032.00
2016-06-30 2,031.00
2016-03-31 1,206.00
2015-12-31 5,294.00
2015-09-30 3,911.00
2015-06-30 2,915.00
2015-03-31 1,251.00
2014-12-31 4,394.00
2014-09-30 2,903.00
2014-06-30 1,676.00
2014-03-31 691.00
2013-12-31 2,393.00
2013-09-30 1,877.00
2013-06-30 1,638.00
2013-03-31 981.00
2012-12-31 3,732.00
2012-09-30 2,418.00
2012-06-30 1,552.00
2012-03-31 608.00
2011-12-31 3,360.00
2011-09-30 2,145.00
2011-06-30 1,905.00
2011-03-31 751.00
2010-12-31 3,426.00
2010-09-30 3,217.00
2010-06-30 2,124.00
2010-03-31 789.00
2009-12-31 2,654.00
2009-09-30 1,909.00
2009-06-30 1,080.00
2009-03-31 573.00
2008-12-31 2,550.00
2008-09-30 1,762.00
2008-06-30 1,230.00
2008-03-31 604.00
2007-12-31 1,271.00
2007-09-30 874.00
2007-06-30 670.00
2007-03-31 343.00
2006-12-31 1,668.00
2006-09-30 1,056.60
2006-06-30 122.70
2006-03-31 217.00
2005-12-31 1,063.20
2005-09-30 886.60
2005-06-30 583.10
2005-03-31 226.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $11.195B $16.659B
TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.
Stock Name Country Market Cap PE Ratio
Dr Reddy's Laboratories (RDY) India $12.006B 34.38
Bausch Health Cos (BHC) Canada $9.867B 6.63
BridgeBio Pharma (BBIO) United States $6.937B 0.00
ASPEN PHARMACR (APNHY) South Africa $5.249B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.556B 14.18
Amphastar Pharmaceuticals (AMPH) United States $0.912B 28.16
Personalis (PSNL) United States $0.856B 0.00
Homology Medicines (FIXX) United States $0.364B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.205B 0.00
Sol-Gel Technologies (SLGL) Israel $0.198B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.172B 0.00
Assembly Biosciences (ASMB) United States $0.157B 0.00
Agile Therapeutics (AGRX) United States $0.124B 0.00
Evoke Pharma (EVOK) United States $0.051B 0.00
China Pharma Holdings (CPHI) China $0.028B 0.00
Teligent (TLGT) United States $0.011B 0.00